摘要
目的探讨右丙亚胺对柔红霉素所致心脏毒性的防治作用。方法观察10例急性非淋巴细胞白血病患者,在接受含柔红霉素化疗时合用右丙亚胺后心电图及左室射血分数(EF)的变化。并与未使用右丙亚胺的对照组12例作比较。结果在柔红霉素方案化疗1个疗程后,右丙亚胺组与对照组心电图异常发生率分别为10.0%(1/10)和25.0%(3/12),左室EF下降超过10%的发生率分别为10%(1/10)和16.7%(2/12),两者差异均无统计学意义。3个疗程后,右丙亚胺组与对照组心电图异常发生率分别为20.0%(2/10)和50.0%(6/12),左室EF分数下降超过10%的发生率分别为20.0%(2/10)和41.7%(5/12)(P<0.01)。对产生心脏毒性的8例患者,在其后再次接受含柔红霉素方案化疗时联合使用右丙亚胺,2个疗程结束后有5例患者异常心电图转为正常,4例患者EF分数得到恢复,无一例心脏损害加重。结论右丙亚胺对柔红霉素所致心脏毒性的发生有一定的防护作用,并且对已经形成的损害有一定的修复作用。
Objective To investigate the protective effects of dexrazoxane on daunorubicin cardiotoxicity. Methods Patients with acute non - lymphoid leukemia were enrolled into chemotherapy group （ Group A, 12 cases） and dexrazoxane combined chemotherapy group （Group B, 10 cases）. ECG and evaluation of ejection fraction （EF） were car- ried out after each course of chemotherapy. Results After the I st course of chemotherapy, the incidences of ECG abnormal were 25.0% （3/12） and 10. 0% （1/10） in the Group A and B, respectively. Meanwhile, incidences of EF reduced by more than 10% were 16. 7% （2/12） and 10. 0% （1/10） in Group A and B, respectively. No significant difference was revealed between the two groups. After the 3rd course of chemotherapy, the incidences of abnormal ECG were 50. 0% （6/12） and 20. 0% （2/10） in Group A and B, respectively. Meanwhile, the incidences of EF reduced by more than 10% were 41.7% （5/12） and 20. 0% （2/10） in Group A and B, respectively. There were significant differences between the two groups （P 〈0. 01 ）. Patients with abnmxnal ECG and reduced EF for more than 10% （8 and 7 cases, respectively） were subsequently treated with 2 courses of dexrazoxane. RecoveIT of ECG and EF was observed in 5 and 4 patients, respectively without recurrence. Conclusion Dexrazoxane confers cardiac protection against daunorubicin cardiotoxicity and reverses daunorubiein- induced heart injury.
出处
《广东医学》
CAS
CSCD
北大核心
2011年第12期1606-1607,共2页
Guangdong Medical Journal
基金
广东省科技计划项目(编号:2010B080701055)
关键词
右丙亚胺
柔红霉素
心脏病
药物疗法
dexrazoxane
daunorubicin
heart diseases
drug therapy
